Organovo Holdings (STU:4OR1) Short Percentage of Float

View and export this data going back to 2013. Start your Free Trial

What is Organovo Holdings Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Organovo Holdings's Short Percentage of Float

For the Biotechnology subindustry, Organovo Holdings's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Organovo Holdings's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's Short Percentage of Float falls into.

Organovo Holdings (STU:4OR1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (STU:4OR1) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

ONVO:USA

Address

11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121

Website

https://www.organovo.com

Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.

Organovo Holdings (STU:4OR1) Headlines

No Headlines